You are about to leave this site and are being redirected to another site. Would you like to leave this site?

Image-1

Image-1

Reveal another side of immunity

BAVENCIO® (avelumab) is an anti-PD-L1 immunotherapy that has been shown in preclinical models to engage both the adaptive and innate immune functions.1-5

AVELUMAB (BAVENCIO) RECOMMENDED BY THE NATIONAL COMPREHENSIVE CANCER NETWORK® NCCN® AS AN OPTION for patients with disseminated Merkel cell carcinoma (category 2A)6

The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

BAVENCIO is the FIRST AND ONLY FDA-approved anti-PD-L1 immunotherapy for adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC)7

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

References: 1. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231-237. 2. Kohrt HE, Houot R, Marabelle A, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4(5):511-527. 3. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295. 4. Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017;17(4):515-523. 5. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148-1157. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Merkel Cell Carcinoma. V.1.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed September 27, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. 7. U.S. National Library of Medicine. DailyMed: Advanced Search. Indication And Usage Section (34067-9). https://dailymed.nlm.nih.gov/dailymed/advanced-search.cfm. Accessed September 26, 2017.